Skip to Main Content

Author Details

Shane Atwell
Lilly Research Laboratories
1994
35
20
Andrej Sali (CM4AI)
PMIDPaper TitleJournal TitlePublished Year
37945533Engineered antigen-binding fragments for enhanced crystallization of antibody:antigen complexes.Protein Sci2024
37279757Epitope topography of agonist antibodies to the checkpoint inhibitory receptor BTLA.Structure2023
32915778Rapid and robust antibody Fab fragment crystallization utilizing edge-to-edge beta-sheet packing.PLoS One2020
31181988Development of tibulizumab, a tetravalent bispecific antibody targeting BAFF and IL-17A for the treatment of autoimmune disease.MAbs2019
29350927Synthesis and Pharmacological Characterization of C4<sub>β</sub>-Amide-Substituted 2-Aminobicyclo[3.1.0]hexane-2,6-dicarboxylates. Identification of (1 S,2 S,4 S,5 R,6 S)-2-Amino-4-[(3-methoxybenzoyl)amino]bicyclo[3.1.0]hexane-2,6-dicarboxylic Acid (LY2794193), a Highly Potent and Selective mGlu<sub>3</sub> Receptor Agonist.J Med Chem2018
30365309Structural Basis for ( S)-3,4-Dicarboxyphenylglycine (DCPG) As a Potent and Subtype Selective Agonist of the mGlu<sub>8</sub> Receptor.J Med Chem2018
29474075Predicting the Conformational Variability of Abl Tyrosine Kinase using Molecular Dynamics Simulations and Markov State Models.J Chem Theory Comput2018
29402739Determination of L-AP4-bound human mGlu8 receptor amino terminal domain structure and the molecular basis for L-AP4's group III mGlu receptor functional potency and selectivity.Bioorg Med Chem Lett2018
29072452Discovery of N-(6-Fluoro-1-oxo-1,2-dihydroisoquinolin-7-yl)-5-[(3R)-3-hydroxypyrrolidin-1-yl]thiophene-2-sulfonamide (LSN 3213128), a Potent and Selective Nonclassical Antifolate Aminoimidazole-4-carboxamide Ribonucleotide Formyltransferase (AICARFT) Inhibitor Effective at Tumor Suppression in a Cancer Xenograft Model.J Med Chem2017
26996964Computationally Designed Bispecific Antibodies using Negative State Repertoires.Structure2016
26627831Channel Gating Regulation by the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) First Cytosolic Loop.J Biol Chem2016
28002967Discovery of (1S,2R,3S,4S,5R,6R)-2-Amino-3-[(3,4-difluorophenyl)sulfanylmethyl]-4-hydroxy-bicyclo[3.1.0]hexane-2,6-dicarboxylic Acid Hydrochloride (LY3020371·HCl): A Potent, Metabotropic Glutamate 2/3 Receptor Antagonist with Antidepressant-Like Activity.J Med Chem2016
27543934Structural basis of selectivity and neutralizing activity of a TGFα/epiregulin specific antibody.Protein Sci2016
26849155Therapeutic Antibody Engineering To Improve Viscosity and Phase Separation Guided by Crystal Structure.Mol Pharm2016
25602126Synthesis and pharmacological characterization of C4-disubstituted analogs of 1S,2S,5R,6S-2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylate: identification of a potent, selective metabotropic glutamate receptor agonist and determination of agonist-bound human mGlu2 and mGlu3 amino terminal domain structures.J Med Chem2015
26313429Synthesis and Pharmacological Characterization of C4-(Thiotriazolyl)-substituted-2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylates. Identification of (1R,2S,4R,5R,6R)-2-Amino-4-(1H-1,2,4-triazol-3-ylsulfanyl)bicyclo[3.1.0]hexane-2,6-dicarboxylic Acid (LY2812223), a Highly Potent, Functionally Selective mGlu2 Receptor Agonist.J Med Chem2015
24463572Generation of bispecific IgG antibodies by structure-based design of an orthogonal Fab interface.Nat Biotechnol2014
22544723Atomic structure of the nuclear pore complex targeting domain of a Nup116 homologue from the yeast, Candida glabrata.Proteins2012
21365675Structure of the C-terminal domain of Saccharomyces cerevisiae Nup133, a component of the nuclear pore complex.Proteins2011
20310066Structures of the autoproteolytic domain from the Saccharomyces cerevisiae nuclear pore complex component, Nup145.Proteins2010
20687163Integrated biophysical studies implicate partial unfolding of NBD1 of CFTR in the molecular pathogenesis of F508del cystic fibrosis.Protein Sci2010
20687133Thermal unfolding studies show the disease causing F508del mutation in CFTR thermodynamically destabilizes nucleotide-binding domain 1.Protein Sci2010
20737437Structure of a putative BenF-like porin from Pseudomonas fluorescens Pf-5 at 2.6 A resolution.Proteins2010
20156452Structures of PHR domains from Mus musculus Phr1 (Mycbp2) explain the loss-of-function mutation (Gly1092--&gt;Glu) of the C. elegans ortholog RPM-1.J Mol Biol2010
20150177Structures of a minimal human CFTR first nucleotide-binding domain as a monomer, head-to-tail homodimer, and pathogenic mutant.Protein Eng Des Sel2010
19934279SGX523 is an exquisitely selective, ATP-competitive inhibitor of the MET receptor tyrosine kinase with antitumor activity in vivo.Mol Cancer Ther2009
18235434Protein production and purification.Nat Methods2008
18542890High throughput protein production and crystallization at NYSGXRC.Methods Mol Biol2008
15507431A novel mode of Gleevec binding is revealed by the structure of spleen tyrosine kinase.J Biol Chem2004
14679545Development of a high-throughput screen for protein catalysts: application to the directed evolution of antibody aldolases.Angew Chem Int Ed Engl2003
11734038Structure of a copper-mediated base pair in DNA.J Am Chem Soc2001
10449721Selection for improved subtiligases by phage display.Proc Natl Acad Sci U S A1999
9353194Structural plasticity in a remodeled protein-protein interface.Science1997
9231898Stable heterodimers from remodeling the domain interface of a homodimer using a phage display library.J Mol Biol1997
7512222Structure of the regulatory domains of the Src-family tyrosine kinase Lck.Nature1994
  • 1 - 35 of 35

Recommended Authors

Department of Pharmaceutical Chemistry, University of California San Francisco
Career Start Year 2012
Number of shared co-authors 1
The Weizmann Institute of Science
Career Start Year 2007
Number of shared co-authors 7
MedImmune Ltd.
Career Start Year 2001
Number of shared co-authors 2
Incyte Corporation
Career Start Year 2000
Number of shared co-authors 3
Poornaprajna Institute of Scientific Research (PPISR)
Career Start Year 1998
Number of shared co-authors 10
Diamond Light Source Ltd, Harwell Science & Innovation Campus
Career Start Year 1998
Number of shared co-authors 4
Pfizer Inc.
Career Start Year 1997
Number of shared co-authors 2
Pfizer Inc.
Career Start Year 1994
Number of shared co-authors 3
University of Texas Southwestern Medical Center
Career Start Year 1993
Number of shared co-authors 2
The Walter and Eliza Hall Institute of Medical Research
Career Start Year 1993
Number of shared co-authors 2
University of California san francisco
Career Start Year 1993
Number of shared co-authors 9
University of Leeds
Career Start Year 1992
Number of shared co-authors 3
Bridge Institute, University of Southern California
Career Start Year 1991
Number of shared co-authors 5
University of Pittsburgh
Career Start Year 1990
Number of shared co-authors 1
University of Georgia
Career Start Year 1990
Number of shared co-authors 4
The Francis Crick Institute
Career Start Year 1989
Number of shared co-authors 2
Fox Chase Cancer Center
Career Start Year 1989
Number of shared co-authors 8
Weizmann Institute of Science
Career Start Year 1988
Number of shared co-authors 6
Leiden Academic Centre for Drug Research (LACDR), Leiden University
Career Start Year 1988
Number of shared co-authors 1
Lilly Research Laboratories
Career Start Year 1988
Number of shared co-authors 4
Boston University
Career Start Year 1987
Number of shared co-authors 1
Indian Institute of Science
Career Start Year 1985
Number of shared co-authors 2
Zuckerman Mind Brain Behaviour Institute
Career Start Year 1982
Number of shared co-authors 20
University of California berkeley
Career Start Year 1982
Number of shared co-authors 3
Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California
Career Start Year 1981
Number of shared co-authors 4
University of California berkeley
Career Start Year 1976
Number of shared co-authors 6
Heartand Lung Research Institute, University of Cambridge
Career Start Year 1971
Number of shared co-authors 4
Columbia University
Career Start Year 1968
Number of shared co-authors 14
University of California San Francisco
Career Start Year 1965
Number of shared co-authors 6
Vanderbilt University
Career Start Year 1954
Number of shared co-authors 8

Collaborators

Co-authored papers 10
The State University of New Jersey
Co-authored papers 9
Eli Lilly and Co.
Co-authored papers 8
Argonne National Laboratory
Co-authored papers 8
New York SGX Research Center for Structural Genomics
Co-authored papers 8
Stanford University
Co-authored papers 8
NYU Langone Hospital - Brooklyn Brooklyn
Co-authored papers 7
Co-authored papers 6
University of California San Francisco
Co-authored papers 5
New York University Grossman School of Medicine
Co-authored papers 5
Co-authored papers 4
University of California san francisco
Co-authored papers 4
Columbia University
Co-authored papers 4
Stanford University
Co-authored papers 3
Co-authored papers 3
Albert Einstein College of Medicine
Co-authored papers 3
US Department of Energy Joint Genome Institute, Lawrence Berkeley National Laboratory
Co-authored papers 3
Creighton University
Co-authored papers 3
Korea Advanced Institute of Science and Technology (KAIST)
Co-authored papers 3
Albert Einstein College of Medicine
Co-authored papers 3
Department of Pharmaceutical Chemistry, University of California San Francisco
Co-authored papers 3
Lilly Research Laboratories
Co-authored papers 3
The Rockefeller University
Co-authored papers 3
The Rockefeller University
Co-authored papers 3
Co-authored papers 2
University of Central Florida
Co-authored papers 2
University of California san francisco
Co-authored papers 2
Co-authored papers 2
Albert Einstein College of Medicine
Co-authored papers 2
Co-authored papers 2